Member Info for MickTKipper

Amino Technologies PLC AMO finnCap Corporate 141.50 141.50 215.00 - Unchanged....SP Target 215p

Amino Technologies* Broker Finncap.

3 reasons to look at Amino

In the first of a series of reminders that we will be delivering on Fridays to
spotlight the opportunities in AIM tech, we reiterate our 215p target price and the
investment case for Amino. After an impressive Capital Markets Day yesterday,
with a tech run through and case studies, the technological excellence that
Amino’s integrated devices earned a strong reputation for is evident in the
software. From a financial point of view, we draw attention to the benefits of
software revenue growth and the increase in recurring revenue. From a structural
point of view we barely need to notify you of the now-default consumer
expectation to view TV content anytime, anywhere and on any device, but also
direct from the content provider platforms as well as from broadcast/telco
platforms – and Amino enables this. From a historical point of view, management
has excelled at ensuring excellence in its supply chain management, margin
maximisation and cash generation. While COVID brings the risk of muddying the
waters for every stock, Amino is in the right place and at the right time during
rapid TV platform evolution.

?Transformation: The transformation to drive software, and decline to pitch in
commoditised device situations, was announced in January 2019, with restructuring
completed by April. Amino integrated devices (set top boxes) are already
differentiated by their software quality, and the acquisition and integration of 24i
Media (acquired July 2019) has accelerated software & services as a proportion of
revenue (now 25%), as well as accelerating growth.

?Structural: Netflix doesn’t run live TV as a platform, so think of the Amino product set
as enabling Netflix plus Sky+, in providing video on demand AND live TV on any
device, anywhere, anytime. Consumers expect this: and it is what each broadband
provider (fixed mobile or cable) needs to provide, to capture more spend and reduce
churn. Smaller telcos don’t have the budgets of Netflix, or Sky, so Amino provides the
in home kit (set top boxes or Smart TV app) as well as the anywhere anytime any
device platform access through a compelling and familiar user experience. Content
providers would also now rather distribute content themselves, on their own platform,
but not all have the budget of Disney+: Amino enables Broadway TV for example,
providing a platform for Broadway online, with great take-up (+4000%) in lockdown.

?Track record: senior management has gained a reputation for margin maintenance
and cash generation, and transparency. Add revenue growth as software grows and
device revenue stabilises at a high margin, and Amino is set to deliver value.

SP Target 215p

https://uk.advfn.com/p.php?pid=legacydaily&epic=L^AMO&type=4&size=3&period=3&ind_type1=1&ind1_1=&ind2_1=&olx_1=3&ma_type1=3&o_1maday1=10&o_2maday1=&o_colour1=1&olx_2=3&ma_type2=3&o_1maday2=50&o_2maday2=&o_colour2=2&olx_3=3&m

A good report on SKY News on Muffers BANGO BGO. So taken a punt.

This sums it up........

"Bango technology has ensured that our customers can enjoy a simple and successful way to buy on Amazon.co.jp " said Toshiaki Hirata , Board Director, Senior Vice President & CSO, SB Payment Service Corp. , a subsidiary of SoftBank Corp . "We look forward to benefiting from Bango data insights to accelerate the growth of our new business".

"Japan's high spending population leads the world in mobile commerce. Charging the cost of goods to the phone bill is a widely adopted payment method, with billions of dollars in online purchases charged to Japanese phone bills," said Paul Larbey, Bango CEO. "The Bango Platform meets the challenge of delivering carrier billing at scale, ensuring global retailers can provide customers with the convenience and security they want from a payment method".

https://uk.advfn.com/p.php?pid=legacydaily&epic=L^BGO&type=4&size=3&period=4&ind_type1=1&ind1_1=&ind2_1=&olx_1=3&ma_type1=3&o_1maday1=10&o_2maday1=&o_colour1=1&olx_2=3&ma_type2=3&o_1maday2=50&o_2maday2=&o_colour2=2&olx_3=3&ma_type3=3&o_1maday3=200&o_2maday3=&o_colour3=3&scheme=&delay_indices=DELAYED_INDICES

Latest broker views

Date Broker Recomm. Current Price Price when issued Old price New price
15 Jun 20 finnCap Corporate 169.00 145.00 225.00

SP Target 225p

UPGRADE for CEY Centamin.........

Centamin PLC CEY Peel Hunt Buy 157.85 158.10 170.00 185.00 Upgrades SP target now 185p

VLX Volex, amazing performance given its earlier trading statement and problems in China beginning of the year.

Volex plc ('Volex'), a global provider of integrated manufacturing services
and power products, today announces its preliminary results for the 53 weeks
ended 5 April 2020 ('FY2020').



Financial Highlights 53 weeks to Year on year change 52 weeks to

5 April 2020 31 March 2019
Revenue $391.4m 5.2% $372.1m
Underlying* operating profit $31.6m 46.3% $21.6m
Statutory operating profit $17.1m 31.5% $13.0m
Underlying* profit before tax $30.4m 50.5% $20.2m
Statutory profit before tax $15.9m 37.1% $11.6m
Statutory profit after tax $14.7m 59.8% $9.2m
Basic earnings per share 9.9c 43.5% 6.9c
Underlying diluted earnings per share 17.3c 36.2% 12.7c
Net cash (before lease liabilities) $31.6m 53.4% $20.6m
Net cash $21.2m 2.9% $20.6m

Citywire......

‘Excellent opportunity’ to buy Greggs, says Jefferies

High street baker Greggs (GRG) is facing challenges but Jefferies says there is currently an ‘excellent opportunity’ to buy the shares.

Analyst Andrew Wade retained his ‘buy’ recommendation and target price of £23.75 on the stock, which rose 5.9% to £17.50 yesterday after updating the market on its store opening schedule.

The social distancing measures Greggs will have to put in place when it opens will result in ‘lower than normal’ sales for some time.

‘Despite the challenges facing the food-to-go sector in the near term, Greggs is better positioned than much of its competition, and we see an excellent opportunity to buy a high quality asset with a clear underlying growth agenda,’ said Wade.

=====================================================================

Needs to get through that resistance at £19 once and for all..

https://uk.advfn.com/p.php?pid=legacydaily&epic=L^GRG&type=4&size=3&period=4&ind_type1=1&ind1_1=&ind2_1=&olx_1=3&ma_type1=3&o_1maday1=10&o_2maday1=&o_colour1=1&olx_2=3&ma_type2=3&o_1maday2=50&o_2maday2=&o_colour2=2&olx_3=3&ma_type3=3&o_1maday3=200&o_2maday3=&o_colour3=3&scheme=&delay_indices=DELAYED_INDICES

HOC....broken out of its bullish flag pattern on the chart .

https://content.screencast.com/users/thomaser/folders/Default/media/f925a502-0f69-462f-8770-9565b7a8e714/hoc%202.jpg

HOC silver and gold SP rising in tandem. Good bullish sign.

https://www.kitco.com/images/live/gold.gif

https://www.kitco.com/images/live/silver.gif?0.6202552414562921

Trades 1,039
Vol. Sold 684,179
Sold Value £1m
Vol. Bought 687,295
Bought Value £1m
PE Ratio 43.379
Earnings 4.576
Dividend 3.507
Yield 1.767%
Not much in it but with both Gold and Spot silver charts moving up again in tandem, good bet this stock will continue to move up.

"Hochschild and Hertz... A review of two old timers by Lucian Miers"

Hochschild and Hertz... A review of two old timers by Lucian Miers
Powerhouse Energy – the legacy of bucket shop placings. Read from Tom Winnifrith HERE

An old friend of mine tipped me the shares of silver miner Hochschild Mining (HOC) at around 70p in late 2008 as the GFC panic was at its peak. When I asked him about the prospects for silver he appeared to be only vaguely aware that this was its game...

He instead pointed out that the company had been founded in 1911 and that any enterprise that had survived two great wars and the great depression was unlikely to go out of business anytime soon, as the share price was suggesting. Naturally, I ignored the old buffer and missed a monster rally to 700p. Hochschild shares briefly traded below 100p during this year’s March sell off and have since doubled. If history is any guide they should trade much higher, regardless of the silver price, and I am long at these levels.

I think it makes sense to treat companies with 100 year plus histories with respect and to think extremely hard before shorting them. My only real foray in this regard was being short Thomas Cook because bankruptcy seemed inevitable. Now we have Hertz (NYSE - HTZ), the 102-year-old car rental company where bankruptcy was announced on 22nd May. I won’t go into the intricacies of chapter 11 filings in the US but I think it is fair to say that there is no way that Hertz’s $18.8 billion of debt will be made whole. This means that shareholders are extremely unlikely to receive anything in the restructuring.

A 39% shareholder, Carl Icahn, seems to have grasped this when he dumped his entire stake for 75 cents a share at the first opportunity after the news. That there was a market bid at this level seems in large part due to a surge in Robin Hood accounts holding Hertz post the bankruptcy filing. These are the small retail army of speculators, who, having been stuck at home with no sport to bet on and recently armed with a cheque from the government, have taken to gambling on stocks like ducks to water and are increasingly seen as the prime driver behind the current market rally. At $1.02 per share, a cent for every year of its existence to date, Hertz is a compelling shorting opportunity which should be seized before the borrow is pulled.

SP upgrade at GRG Greggs ...Greggs PLC GRG HSBC Hold 1,727.00 1,727.00 2,000.00 - Upgrades

New SP target 2000p

GRG Greggs latest trade dealls.......

Trades 4,105

Vol. Sold 206,982
Sold Value £4m
Vol. Bought 253,306
Bought Value £4m
PE Ratio 20.197
Earnings 86.20
Dividend 33.00
Yield 1.895%

Gone long on Greggs GRG.......reckon its going to attack that 1900p resistance tomorrow and the day after.

Greggs : HSBC raises to hold from reduce

https://uk.advfn.com/p.php?pid=legacydaily&epic=L^GRG&type=4&size=3&period=4&ind_type1=1&ind1_1=&ind2_1=&olx_1=3&ma_type1=3&o_1maday1=10&o_2maday1=&o_colour1=1&olx_2=3&ma_type2=3&o_1maday2=50&o_2maday2=&o_colour2=2&olx_3=3&ma_type3=3&o_1maday3=200&o_2maday3=&o_colour3=3&scheme=&delay_indices=DELAYED_INDICES

Present trades...........

AVCT Avacta.....

Trades 1,557

Vol. Sold 1,123,955
Sold Value £2m
Vol. Bought 1,676,693
Bought Value £2m
PE Ratio -15.925
Earnings -8.76
Dividend 0.00
Yield

CFWD............

On a sum-of-the-parts analysis, it is easy to generate a valuation that is substantially in excess of the current market capitalisation.

Its a Bargain BUY at the moment look at the broker comment this morning. ..........

AVCT Avacta.....

Trades 1,557

Vol. Sold 1,123,955
Sold Value £2m
Vol. Bought 1,676,693
Bought Value £2m
PE Ratio -15.925
Earnings -8.76
Dividend 0.00
Yield

Avacta* Fundraise of £48m – pursuing multiple opportunities

Avacta has conditionally raised £45m net to (i) accelerate the expansion of its therapeutics pipeline, given recent pre-clinical data for both its pre|CISION and TMAC drug conjugate platforms, and (ii) provide the necessary working capital to fund the development and deployment of a COVID-19 antigen test in the summer of 2020 as well as scale its broader diagnostics business more rapidly. These funds will also generate first-in-man data (safety and tolerability) for the Affimer platform, which will significantly de-risk the platform in the eyes of potential pharma partners, accelerate its partnership model and substantially increase future deal values. We leave our target price under review, although using a SOTP analysis, it is easy to generate a valuation that is substantially in excess of the current market capitalisation.

? Conditional funding raised £45m net, by way of the issue of 40.0m shares at 120p, representing 16.1% of the enlarged equity. Of this, c.£10m will be used to fund the diagnostics business, with c.£35m allocated to the therapeutics business. ? Diagnostic business – £10m to provide working capital for (i) the COVID-19 testing opportunity, (ii) expansion of in-house product development capabilities and (iii) acceleration of its broader diagnostics product pipeline and commercial partnerships. ? Therapeutics pipeline expansion – £35m to (i) develop the pre|CISION pipeline of targeted chemotherapies and deliver multiple pre-clinical assets and at least one more IND filing in addition to AVA6000, (ii) file an IND for its first Affimer therapeutic being a TMAC drug conjugate or a bispecific based on the AVA004 PD-L1 inhibitor, (iii) expand the Affimer immunotherapy pipeline and (iv) generate first-in-human data for the Affimer platform. Avacta is already funded to complete clinical Phase I (safety & tolerability) testing in the UK of its first pre|CISION chemotherapy (AVA6000). ? Valuation. Our target price remains under review, given the difficulty of forecasting revenues of a SARS-CoV-2 antigen test with any degree of accuracy.

Suffice to say, if Avacta is able to successfully develop a test(s) in the time frame indicated (CE mark and launch in summer), the valuation upside is considered substantial. Its pipeline of targeted chemotherapies (pre|CISION) and enhanced immune-oncology assets (TMACs), albeit with incremental development risk, drives significant long term shareholder value in our view, and certainly commands a valuation of c.£150m (previous target valuation), based on comparable companies and the current stage of clinical development. On a sum-of-the-parts analysis, it is easy to generate a val

Latest broker views

Date Broker Recomm. Current Price Price when issued Old price New price
08 Jun 20 finnCap Corporate 139.50 157.00 - -

SP target short time 157p

After todays tie up, broker backing for oxb Oxford BIO.........

Oxford BioMedica PLC OXB Liberum Capital Buy 805.00 774.00 1,090.00 - Reiterates

Oxford BioMedica PLC OXB Peel Hunt Buy 805.00 774.00 1,060.00 - Reiterates

BUZZ – Oxford Biomedica: Rises on signing agreement with VMIC
08-06-2020 09:58
* Shares of gene and cell therapy firm rise as much as 6.2% to 822 pence after it signed an agreement with a group backed by the UK government to help it scale up production of AstraZeneca's potential COVID-19 vaccine
* Stock sees biggest intraday percentage gain since May 28 and is at its highest since October 2018
* Co agrees to a five-year partnership with the Vaccines Manufacturing and Innovation Centre for equipment at its facility in Oxford, UK, which would also help it make other vaccines
* Last month, AstraZeneca partnered with Oxford Biomedica, spun off from the University of Oxford in 1995, for its experimental COVID-19 vaccine
(Reporting by Samantha Machado in Bengaluru) ((Samantha.machado@thomsonreuters.com)

Questor have sought out what I think will be a winner especially if the Warm weather returns. think Ill be buying monday first hour, depends on the spread.

Coca-Cola Hellenic /.............cch

Questor: tourists are about to return – and that’s good news for this Coca-Cola bottler

Questor share tip: shares in Coca-Cola Hellenic Bottling Company have lost their sparkle in the Covid crisis and now look tempting

By
James Ashton
7 June 2020 • 6:00am

What a joy it would be to tour some of Europe’s greatest sights this summer. Many Britons will settle for a seaside staycation instead of braving the new quarantine – and, if other travellers do the same, the likes of Rome’s Colosseum and the Acropolis overlooking Athens will be less trafficked than usual, thronged with fewer tourists toting selfie sticks and slurping from bucket-sized Cokes with ice.

But chances are these destinations will not be empty. Many European countries are scrambling to reopen and lure the cautious tourist dollar.

From June 15 Greece is welcoming visitors from 29 countries (although not Britain), while Italian cinemas and theatres will be allowed to reopen following restaurant and bar re-openings in a country that not so long ago was the European centre of Covid-19....

You’ve reached your free article limit...

CCH charts...........

https://uk.advfn.com/p.php?pid=legacydaily&epic=L^CCH&type=4&size=3&period=7&ind_type1=1&ind1_1=&ind2_1=&olx_1=3&ma_type1=3&o_1maday1=10&o_2maday1=&o_colour1=1&olx_2=3&ma_type2=1&o_1maday2=50&o_2maday2=&o_colour2=2&olx_3=3&ma_type3=1&o_1maday3=200&o_2maday3=&o_colour3=3&scheme=&delay_indices=DELAYED_INDICES

Latest broker views

Date Broker Recomm. Current Price Price when issued Old price New price
20 May 20 Goldman Sachs Neutral 2,164.00 1,861.00 2,330.00 2,230.00
11 May 20 Deutsche Bank Buy 2,164.00 1,896.50 2,400.00 -
07 May 20 Liberum Capital Buy 2,164.00 1,928.00 3,335.00 -
27 Apr 20 Barclays Capital Overweight 2,164.00 1,975.00 2,620.00 -
08 Apr 20 Credit Suisse Outperform 2,164.00 1,951.50 3,200.00 2,500.00
02 Apr 20 Deutsche Bank Buy 2,164.00 1,687.00 3,250.00 2,450.00
30 Mar 20 Jefferies International Buy 2,164.00 1,628.003,300.00 2,300.00

Directors being buying as well over last couple of months.